{"id":975975,"date":"2026-06-25T16:33:24","date_gmt":"2026-06-25T20:33:24","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/"},"modified":"2026-06-25T16:33:24","modified_gmt":"2026-06-25T20:33:24","slug":"cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/","title":{"rendered":"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">NEW YORK, June  25, 2026  (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4<sup>th <\/sup>floor, 75013 Paris, France.<\/p>\n<p align=\"justify\">At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors.<\/p>\n<p>The detailed results of the vote and the resolutions are available on Cellectis\u2019 website:<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=30YHJrCX6thhXfOPpDGwS8xz4XvhmnkOumzFRjDIYP6A27ZzcJEX0jaNNn6rqGJHpaSv9xzKRKUqmh2c3mtU_mNrrZF5rdO7gNu1-uyC8pr6sypDYqf2SlK3pDV-bck1Lo_Et2qB5mA3knof3ilKy0K_B2Ggxa1uFces6FWGs96DW2iakTQYWI3B2dtD7V6j\" rel=\"nofollow\" target=\"_blank\">https:\/\/www.cellectis.com\/en\/investors\/general-meetings\/<\/a><\/p>\n<p align=\"justify\">\n        <strong>About\u202fCellectis<\/strong>\u202f\u202f\u202f\u202f\u202f<br \/>Cellectis\u202fis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company\u202futilizes\u202fan allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and\u202fready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities,\u202fCellectis\u202fis one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish.\u202f\u202f\u202f\u202f\u202f<br \/>\u202f\u202f\u202f\u202f<br \/>Cellectis\u2019 headquarters are in Paris, France, with locations in New York and Raleigh, NC.\u202fCellectis\u202fis listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). <br \/>To find out more, visit\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a9TNXdbOvVosuk6o5U47V8lBVofDxGziHr0ZiqLtXOdz5Yc4z8GNG8KC13tEF2xop76g954KdYhEEUDHY7Vm6iwUGSxYzITKioV-BapGfEU=\" rel=\"nofollow\" target=\"_blank\">www.cellectis.com<\/a>\u202fand follow\u202fCellectis\u202fon\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=f_0llp4QU43gQlLmt-ytD5dI-LbGptHuJbfjb7bo5Yzf1qdGZMJTIZqCF_ZjDM6sDxvWj2AAGks2-uTJt7kBUwqad9odmUNkOKKjO1ztBDgqY9GHMNY0R6Irej6EQgKc\" rel=\"nofollow\" target=\"_blank\">LinkedIn<\/a>\u202fand\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9-X69mgzAYgo0k_X1vKVi7DvV1h93nM-vBWolnQIELynUxXGniT7WMzqEAPM7IIxRjbnpnJmVwuC06-S83uKNg==\" rel=\"nofollow\" target=\"_blank\">X<\/a>.\u202f\u202f<\/p>\n<p align=\"justify\">\n        <strong>For further information on\u202fCellectis, please contact:<\/strong>\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f<br \/>\u202f\u202f\u202f\u202f\u202f<br \/><strong>Media contacts:<\/strong><br \/>Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=a9L-FVeGRmyNnZrC5XblDQIMH5SQogZKruFJvdD9zZGHqBsOJ-XTsFV6ssiLFz7TtO7jGdTrS3xFTw8wyi6a_m2C6E0iAKGtGULRJ1Gocg0=\" rel=\"nofollow\" target=\"_blank\">media@cellectis.com<\/a>\u202f<br \/>Patricia Sosa Navarro, Chief of Staff to the CEO,\u202f+33 (0)7 76 77 46 93\u202f\u202f\u202f\u202f\u202f\u202f<\/p>\n<p align=\"justify\">\n        <strong>Investor Relations contact:<\/strong>\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f\u202f<br \/>Arthur Stril, Chief Financial Officer &amp; Chief Business Officer,\u202f<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=buXvPUIsgihBuy6peL3pZ3CBDNkDZMsPjpWlT8DE5lz9Cgh4n-rzfhg7y3sYkyWugMxXqk3IqLYuVlk6KUFi1t-J4IWdV9WsM-8pGmObsPw=\" rel=\"nofollow\" target=\"_blank\">investors@cellectis.com<\/a><\/p>\n<p id=\"gnw_attachments_section-header\">\n        <strong>Attachments<\/strong>\n      <\/p>\n<ul id=\"gnw_attachments_section-items\">\n<li>\n          <a href=\"https:\/\/ml.globenewswire.com\/Resource\/Download\/77b3bdf8-2bfd-4c13-8c55-6d237556aa0d\" rel=\"nofollow\" target=\"_blank\">Cellectis GM June 25, 2026 &#8211; PR voting results.pdf<\/a>\n        <\/li>\n<\/ul>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MjdlMGMwNjctMGRlOC00ZjJmLWE5MjMtYzg5MTYwZTYzNDhiLTEwNjE0NDgtMjAyNi0wNi0yNS1lbg==\/tiny\/Cellectis-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis\u2019 website:https:\/\/www.cellectis.com\/en\/investors\/general-meetings\/ About\u202fCellectis\u202f\u202f\u202f\u202f\u202fCellectis\u202fis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company\u202futilizes\u202fan allogeneic &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-975975","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis\u2019 website:https:\/\/www.cellectis.com\/en\/investors\/general-meetings\/ About\u202fCellectis\u202f\u202f\u202f\u202f\u202fCellectis\u202fis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company\u202futilizes\u202fan allogeneic &hellip; Continue reading &quot;Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-25T20:33:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026\",\"datePublished\":\"2026-06-25T20:33:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/\"},\"wordCount\":287,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/\",\"name\":\"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=\",\"datePublished\":\"2026-06-25T20:33:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/","og_locale":"en_US","og_type":"article","og_title":"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - Market Newsdesk","og_description":"NEW YORK, June 25, 2026 (GLOBE NEWSWIRE) &#8212; Cellectis (the \u201cCompany\u201d) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today its shareholders general meeting at 2:30 p.m. CET at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France. At the meeting, during which approximately 55,84% of voting rights were exercised, resolutions 1 through 29 were adopted, while resolution 30 was rejected, consistent with the recommendations of the board of directors. The detailed results of the vote and the resolutions are available on Cellectis\u2019 website:https:\/\/www.cellectis.com\/en\/investors\/general-meetings\/ About\u202fCellectis\u202f\u202f\u202f\u202f\u202fCellectis\u202fis a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company\u202futilizes\u202fan allogeneic &hellip; Continue reading \"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/","og_site_name":"Market Newsdesk","article_published_time":"2026-06-25T20:33:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026","datePublished":"2026-06-25T20:33:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/"},"wordCount":287,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/","name":"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=","datePublished":"2026-06-25T20:33:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc1Mjc0MSM3Njc4NzEzIzIwNDk4Nzc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/cellectis-reports-results-from-shareholders-meeting-held-on-june-25-2026\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Cellectis Reports Results from Shareholders Meeting Held on June 25, 2026"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/975975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=975975"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/975975\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=975975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=975975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=975975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}